Article

Beyond Efficacy: Policy, Delivery, and Equity Determinants of Long-Acting Monoclonal Antibody Uptake for Infant RSV Prevention—A WAidid Consensus Document

2026-07-20

Abstract excerpt

<h4>Background: </h4> Long-acting monoclonal antibodies have become an important strategy for pre-venting respiratory syncytial virus (RSV) disease in infants. Nirsevimab is the first product for which substantial post-licensure implementation data are available, whereas real-world evidence on clesrovimab remains limited. Although nirsevimab has demonstrated high efficacy, its uptake varies considerably across cou...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f6f71f7a-9085-5841-9334-c89cccac08c9
DOI: 10.20944/preprints202607.1445.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Beyond Efficacy: Policy, Delivery, and Equity Determinants of Long-Acting Monoclonal Antibody Uptake for Infant RSV Prevention—A WAidid Consensus DocumentDOI 10.20944/preprints202607.1445.v1Read

Cost-effectiveness of the next generation of RSV intervention strategiesSemantic proximity Read

Respiratory Syncytial virus Strain Evolution and Mutations in Western Australia in the Context of Nirsevimab ProphylaxisSemantic proximity Read

Evaluation of Antibody-based Preventive Alternatives for Respiratory Syncytial Virus: A Novel Multi-Criteria Decision Analysis Framework and Assessment of Nirsevimab in SpainSemantic proximity Read

Bivalent RSVpreF effectiveness against RSV-related lower respiratory tract disease hospitalization and ED visits across three RSV SeasonsSemantic proximity Read

Population Impact of a hybrid strategy combining maternal RSV vaccination and nirsevimab immunization on lower respiratory tract infections in infants under 1 year in Bogotá: a counterfactual analysisSemantic proximity Read

Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trialsSemantic proximity Read

Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in France.Semantic proximity Read

Safety Profile of the Bivalent RSVpreF Vaccine (Abrysvo®) Administered During Pregnancy: An Active Real-World Pharmacovigilance Study in Panama, 2025Semantic proximity Read

Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South AfricaSemantic proximity Read

Surveillance-based estimation of the impact of introducing a pathfinder programme for nirsevimab immunisation in Ireland on infant hospitalisations due to respiratory syncytial virus in 2024/2025Semantic proximity Read

Pregnant women's choices for preventing respiratory syncytial virus (RSV)Semantic proximity Read

The long road to protect infants against severe RSV lower respiratory tract illnessSemantic proximity Read